Video

VIDEO: What was the most interesting thing you learned at the meeting?


 

AT SABCS 2014

References

SAN ANTONIO – Our reporter Michele Sullivan asked selected attendees at the San Antonio Breast Cancer Symposium to identify the most interesting or practice-changing study presented at the meeting. The answer was the same across the board - the Suppression of Ovarian Function Trial (SOFT), which showed that selective ovarian suppression reduces disease recurrence in women with early breast cancer.

In our video interview clinicians respond to the implications of the data in their practice.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

No increase in prostate cancer with testosterone therapy
MDedge Hematology and Oncology
Brentuximab changes landscape for post-transplant Hodgkin’s lymphoma patients
MDedge Hematology and Oncology
More activity, less television prolongs life in colorectal Ca
MDedge Hematology and Oncology
Ultrasound screening for dense breasts is high cost, offers little benefit
MDedge Hematology and Oncology
Cancer patients with incidental VTE have high risk of recurrent thrombi
MDedge Hematology and Oncology
Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients
MDedge Hematology and Oncology
VIDEO: High TILs associated with less efficacy from trastuzumab
MDedge Hematology and Oncology
North America has highest rate of obesity-related cancers
MDedge Hematology and Oncology
Adjuvant capecitabine adds no advantage to bisphosphonate in elderly breast cancer patients
MDedge Hematology and Oncology
SOFT trial endorses selective ovarian suppression in early breast cancer
MDedge Hematology and Oncology

Related Articles